RPS16-2 Antibody

What is RPS16 and why is it important in research?

RPS16 is the 40S ribosomal protein S16 belonging to the ribosomal protein S9P family. It is located in the cytoplasm and can be acetylated. This protein is extensively involved in fundamental cellular processes including rRNA processing, translational elongation, initiation, and termination through its RNA binding activity. The importance of RPS16 in research stems from its critical role in protein synthesis machinery and its implications in various pathological conditions, including certain cancers. Studies have shown that the USP1-RPS16 axis is involved in hepatocellular carcinoma (HCC) cell proliferation, making it a potential target for therapeutic interventions .

What are the main applications for RPS16 antibodies in research?

RPS16 antibodies are versatile tools in molecular and cellular biology research with multiple validated applications. They are commonly used in Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Immunocytochemistry (ICC), and Enzyme-Linked Immunosorbent Assay (ELISA) techniques . Some specialized RPS16 antibody pairs are also validated for Cytometric bead array applications . These diverse applications make RPS16 antibodies valuable for studying protein expression, localization, and interactions in various experimental contexts. Researchers commonly employ these antibodies to investigate ribosomal biology, protein synthesis mechanisms, and disease-related alterations in RPS16 expression or function.

What cell lines have been validated for RPS16 antibody detection?

Several cell lines have been validated for successful detection of RPS16 using specific antibodies. According to testing data, HeLa cells and Jurkat cells have shown positive results in Western Blot applications . MCF-7 cells have been validated for Immunofluorescence and Immunocytochemistry applications . Additionally, HepG2 cells have been used successfully in research studying RPS16 in the context of hepatocellular carcinoma . These validated cell lines provide researchers with reliable experimental models for studying RPS16 expression, localization, and function across different cellular contexts and applications.

How does the USP1-RPS16 axis influence cancer cell proliferation?

The USP1-RPS16 axis has been identified as a significant factor in cancer cell proliferation, particularly in hepatocellular carcinoma (HCC). Research has demonstrated that ablation of the USP1-RPS16 axis markedly reduces proliferation of HCC cells . The mechanism involves ubiquitin-mediated protein stability regulation. Investigations have shown that both pharmacological inhibition (using ML323) and genetic inhibition (using RNAi) of USP1 can reduce the expression of RPS16, while having no effect on other ribosomal proteins like RPS4X and RPS18 . Furthermore, treatment with Bortezomib (BTZ), a specific inhibitor of proteasome, increased the protein expression of RPS16 in HepG2 cells, suggesting that RPS16 can be degraded through the ubiquitin-proteasome pathway . These findings indicate that USP1 likely acts as a deubiquitinating enzyme that stabilizes RPS16 by preventing its proteasomal degradation, thereby promoting cancer cell proliferation.

What is the significance of binding domains between USP1 and RPS16?

The binding domains between USP1 and RPS16 represent crucial interaction sites that determine the functional relationship between these proteins. Researchers have employed sophisticated approaches to identify these domains, including the engineering of truncated mutants of USP1 fused with FLAG-tag on their C-terminals (TM1, TM2, TM3, and TM4) and co-transfection with HA-RPS16 into HEK293T cells . This methodological approach allows for the precise mapping of protein-protein interaction regions. Understanding these binding domains is significant because it provides insights into the molecular mechanism through which USP1 regulates RPS16 stability. This knowledge can potentially lead to the development of targeted interventions that disrupt the USP1-RPS16 interaction, which may have therapeutic implications in diseases where this axis is dysregulated, such as hepatocellular carcinoma. The identification of specific binding domains also facilitates structure-based drug design approaches aimed at modulating this interaction.

How can RPS16 antibodies be used to study post-translational modifications?

RPS16 antibodies represent powerful tools for investigating post-translational modifications (PTMs) of this important ribosomal protein. Since RPS16 can be acetylated , researchers can employ specific antibodies to study these modifications through various techniques. Immunoprecipitation followed by mass spectrometry analysis can identify acetylation sites and other potential PTMs on RPS16. For this approach, researchers typically couple antibodies to dynabeads using an Antibody Coupling Kit and incubate them with cell lysates for 1-2 hours . The protein-dynabeads-antibody complexes are then processed for mass spectrometry or western blotting analysis. Additionally, researchers can combine RPS16 antibodies with modification-specific antibodies (e.g., anti-acetyl lysine) in co-immunoprecipitation experiments followed by western blotting to detect acetylated forms of RPS16. These methodologies enable detailed studies of how PTMs regulate RPS16 functions in normal physiology and disease states, providing insights into translation regulation mechanisms.

What are the optimal dilution ratios for different RPS16 antibody applications?

The optimal dilution ratios for RPS16 antibodies vary significantly depending on the specific application and the antibody formulation being used. Based on validated protocols, researchers should consider the following recommended dilutions:

It is strongly recommended that researchers titrate these antibodies in each testing system to obtain optimal results, as the performance may be sample-dependent . Additionally, preliminary experiments with serial dilutions can help identify the optimal concentration that provides the best signal-to-noise ratio for each specific experimental context.

How should co-immunoprecipitation be optimized for studying RPS16 interactions?

Optimizing co-immunoprecipitation (Co-IP) for studying RPS16 interactions requires careful consideration of several methodological factors. Based on successful research protocols, the following approach is recommended:

First, researchers should use an Antibody Coupling Kit to prepare dynabeads coupled with anti-RPS16 antibodies. The dynabeads should be incubated with the specified antibodies for 16-24 hours to ensure proper coupling . Following this, the antibody-coupled beads are incubated with cell lysates extracted from the experimental cells for 1-2 hours to capture RPS16 and its interacting proteins.

The protein-dynabeads-antibody complexes are then mixed with blue SDS-binding buffer and subjected to incubation in 70°C water for 10 minutes to dissociate the protein complexes . After centrifugation at 13,000 rpm for 2 minutes, the supernatant containing the interacting proteins can be collected for further analysis.

For robust results, several optimization steps should be considered: (1) adjusting lysis buffer composition to preserve protein-protein interactions while ensuring efficient cell lysis; (2) testing different antibody-to-bead ratios; (3) varying the amount of starting material; (4) optimizing incubation times and temperatures; and (5) including appropriate controls such as IgG controls and input samples. These methodological refinements help ensure specific and reproducible detection of genuine RPS16 interaction partners.

What factors affect antibody specificity in RPS16 detection?

Several critical factors can influence antibody specificity in RPS16 detection, which researchers must consider for reliable experimental outcomes. First, the type of antibody—polyclonal versus monoclonal—significantly impacts specificity. Polyclonal antibodies like the 15603-1-AP recognize multiple epitopes and may offer higher sensitivity but potentially lower specificity compared to monoclonal antibodies such as those in the MP50839-1 matched pair .

The immunogen used for antibody production also affects specificity. For instance, the 15603-1-AP antibody was raised against full-length RPS16 of human origin, while the A05230 antibody used a recombinant fusion protein of human RPS16 as the immunogen . These different immunization strategies may result in antibodies recognizing distinct epitopes with varying specificity profiles.

Experimental conditions, including fixation methods, antigen retrieval techniques, and blocking protocols, can dramatically influence antibody specificity. For immunohistochemistry applications with the 15603-1-AP antibody, antigen retrieval with TE buffer pH 9.0 is specifically recommended, although citrate buffer pH 6.0 may be used as an alternative . This highlights the importance of optimizing these parameters for each experimental system.

Cross-reactivity with related proteins is another consideration, particularly given that RPS16 belongs to the ribosomal protein S9P family. Researchers should validate antibody specificity through appropriate controls, including knockdown or knockout samples, to ensure the observed signals are specifically attributable to RPS16 rather than related proteins.

How can researchers address discrepancies in observed molecular weight?

Discrepancies in the observed molecular weight of RPS16 can be a significant source of confusion for researchers. While the calculated molecular weight of RPS16 is approximately 16 kDa, which aligns with observations from most antibodies like the 15603-1-AP , some antibodies such as the A05230 from Boster Bio report an observed molecular weight of 111 kDa . This substantial difference requires careful consideration and troubleshooting.

To address these discrepancies, researchers should first verify that the detected band truly represents RPS16 by employing additional validation techniques. These might include using alternative antibodies targeting different epitopes of RPS16, performing siRNA knockdown experiments to confirm signal reduction, or analyzing mass spectrometry data of the immunoprecipitated protein.

Post-translational modifications such as ubiquitination, SUMOylation, or glycosylation can significantly increase the apparent molecular weight of proteins. Since RPS16 is known to be subject to ubiquitin-mediated degradation , researchers should consider whether such modifications might explain the higher molecular weight observation. Additionally, RPS16 can form protein complexes that may not fully dissociate under standard SDS-PAGE conditions, potentially resulting in higher molecular weight bands.

Experimental conditions, including the percentage of the polyacrylamide gel, running buffer composition, and sample preparation protocols, can all influence protein migration patterns. Researchers observing unexpected molecular weights should systematically optimize these parameters while including appropriate molecular weight markers and positive controls.

What strategies can improve signal detection in challenging samples?

Improving signal detection for RPS16 in challenging samples requires a multi-faceted approach addressing various aspects of the experimental workflow. For samples with low RPS16 expression, signal amplification techniques can be employed. For Western blotting, more sensitive detection substrates such as enhanced chemiluminescence (ECL) plus or femto-sensitivity reagents can significantly improve signal detection. For immunohistochemistry or immunofluorescence applications, tyramide signal amplification (TSA) or quantum dots-based detection systems might be considered.

Optimization of sample preparation is crucial for challenging samples. For tissues with high lipid content or dense extracellular matrix, modified extraction protocols may be necessary. Extended antigen retrieval times or alternative retrieval buffers might be required for formalin-fixed paraffin-embedded tissues. As noted in the product information for the 15603-1-AP antibody, TE buffer pH 9.0 is recommended for antigen retrieval, though citrate buffer pH 6.0 may serve as an alternative .

Antibody concentration and incubation conditions should be systematically optimized for challenging samples. While the recommended dilution ranges are 1:500-1:1000 for Western blot, 1:20-1:200 for IHC, and 1:10-1:100 for IF/ICC with the 15603-1-AP antibody , challenging samples might require adjustments to these ranges. Extended primary antibody incubation times, often at 4°C overnight, can improve sensitivity while maintaining specificity.

Signal-to-noise ratio can be enhanced by modifying blocking solutions (testing different blocking agents such as BSA, milk, normal serum, or commercial blocking solutions) and increasing washing stringency. Additional background reduction strategies include pre-adsorption of secondary antibodies and optimization of secondary antibody concentrations.

How can RPS16 antibodies contribute to cancer research?

RPS16 antibodies serve as valuable tools in cancer research, offering insights into fundamental mechanisms of cancer biology. Recent studies have established a significant connection between RPS16 and cancer progression, particularly in hepatocellular carcinoma (HCC). Research has demonstrated that the USP1-RPS16 axis markedly influences the proliferation of HCC cells, positioning RPS16 as a potential therapeutic target .

Immunohistochemical analysis using anti-RPS16 antibodies enables researchers to evaluate RPS16 expression patterns in various cancer tissues, facilitating correlation with clinical parameters such as tumor stage, grade, and patient outcomes. The 15603-1-AP antibody has been validated for immunohistochemistry in human breast cancer tissue, highlighting its utility in oncological research .

RPS16 antibodies can be employed in mechanistic studies investigating ribosomal biogenesis and protein synthesis dysregulation in cancer cells. By coupling RPS16 antibodies with techniques such as polysome profiling or ribosome footprinting, researchers can examine how alterations in RPS16 impact translation patterns in malignant cells.

For in vivo studies, RPS16 antibodies serve critical functions in analyzing xenograft models. Researchers have used anti-RPS16 antibodies alongside proliferation markers like Ki67 in immunohistochemical analysis of HepG2 xenografts to assess tumorigenic properties . This approach allows for the evaluation of potential therapeutic interventions targeting the RPS16 pathway.

Investigating the post-translational modifications of RPS16 in cancer contexts represents another promising application. Given the established role of the ubiquitin-proteasome pathway in regulating RPS16 stability , antibodies specific to modified forms of RPS16 could provide valuable insights into the dysregulation of these processes in cancer cells.

What emerging technologies are enhancing RPS16 research?

Emerging technologies are revolutionizing RPS16 research, offering unprecedented insights into its functions and interactions. Proximity labeling techniques such as BioID and APEX are being increasingly applied to study ribosomal proteins including RPS16. These approaches involve expressing RPS16 fused to a biotin ligase or peroxidase, which biotinylates proteins in close proximity when activated. This enables the identification of transient or weak interactions that might be missed by traditional co-immunoprecipitation approaches, providing a more comprehensive understanding of the RPS16 interactome.

Advancements in mass spectrometry technologies are enhancing the detection and characterization of RPS16 post-translational modifications. High-resolution mass spectrometry combined with enrichment strategies using RPS16 antibodies allows researchers to map acetylation, ubiquitination, and other modifications with unprecedented precision, revealing how these modifications regulate RPS16 function in various cellular contexts.

CRISPR-Cas9 genome editing is transforming functional studies of RPS16. Researchers can now generate precise modifications to the RPS16 gene, creating cellular models with specific mutations, deletions, or tagged versions of the endogenous protein. These models can be particularly valuable for studying the effects of RPS16 variants identified in diseases or for creating reporter systems to monitor RPS16 expression and localization in real-time.

Single-cell analyses incorporating RPS16 antibodies are providing insights into cell-to-cell variability in ribosomal composition and function. Technologies such as single-cell Western blotting, mass cytometry (CyTOF), and imaging mass cytometry allow researchers to examine RPS16 expression patterns at the single-cell level, potentially revealing subpopulations with distinct translational properties within heterogeneous samples like tumors.

The development of specialized RPS16 antibody pairs optimized for cytometric bead array applications reflects the trend toward multiplexed detection systems. These emerging platforms enable simultaneous quantification of multiple proteins, including RPS16 and its interaction partners, from limited sample volumes, enhancing the efficiency and comprehensiveness of ribosomal protein research.